SBIR/STTR Research Award

Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes

Award identifier d19053fc5991fc4fde3053fd6c8d96b38cdcdc9b81b1a0814295de3a828a0317Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$288,767

Program and phase

STTR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BLOTTING INNOVATIONS, INC
Proposal award date
2022-09-22
Contract end date
2023-09-21
UEI
PXLEUBUM3JS7
Solicitation number
PA21-262
Topic code
400

Research abstract

PROJECT SUMMARY The goal of this Phase I STTR is for Blotting Innovations, LLC to establish feasibility of a commercializable mesowestern—a high-throughput, affordable western blotting technique that we recently developed. Western blotting is a technique for molecular-weight-resolved analysis of proteins and their post-translational modifications that is practiced today almost identically to when it was first introduced in the late 1970s. It remains one of the most widely-used protein assays across biomedical research, perhaps the most used in the past 10 years. Major reasons are that it is low-cost, often a gold standard, and well-established in most labs. Yet, western blotting has been refractory to scale up, typically limited to ~10 samples per run. Capillary electrophoresis-based separation in automated apparati has been developed that increase throughput with smaller samples, but are expensive and can be sensitive to sample preparation. The microwestern uses piezoelectric pipetting for up to 96 blots at a time in a standard footprint; however, the piezoelectric apparatus imposes capital cost and technical difficultly deterrents. We established the mesowestern that analyzes over 300 samples with a similar footprint, affordability, and ease-of-use as traditional western blots, and with ~10-fold lower sample size requirements. Our main products are a precast mesowestern gel that is loadable by a low-cost pipetting robot (opentrons) and a novel yet affordable tank for immersed horizontal electrophoresis of the loaded precast gel. A main innovation is a customizable gel casting device that produces polyacrylamide gels with hundreds of ~1 uL wells, and associated protocols for robust gel casting and electrophoresis. Another main innovation is immersed horizontal tank electrophoresis for polyacrylimide gels; only semi-dry horizontal (microwestern) or immersed vertical tank (traditional) are currently available. Phase I Hypothesis. Can precast mesowestern gels be robustly-loaded robotically, and then subjected to immersed horizontal tank electrophoresis? We hypothesize that this can be accomplished by designing a rigid insert that holds the gel during casting and shipping but also fits into (i) opentrons pipetting robots and (ii) a low-cost, horizontal immersed electrophoresis apparatus. We have two Aims that will establish feasibility of the product by testing this hypothesis. In Aim 1, we will establish robust robotic loading of shipped, precast mesowestern gels. We focus on Opentrons micropipetting robots that are easy to use and very affordable. In Aim 2, we will establish robust electrophoresis of robotically-loaded mesowestern gels. Success in each aim is defined by variability (CV%) across analytes and technicians to be andlt;10%. We expect to have a beta-testable product at the end of Phase I. Phase II would focus on expanding to different sample types (e.g. Immunoprecipitation-western) and across antibodies, as well as on robust transfer to membrane (another main variability source). Our market is academic research labs and pre-clinical pharmaceutical Randamp;D labs.PROJECT NARRATIVE Proteins and their post-translational modifications functionally control most of biology. Western blotting is a reliable method for analyzing them but has remained largely unchanged for over 40 years, and is low throughput. This proposal develops a feasible product for the mesowestern technology, which enables high-throughput western blotting with minimal deviation from the already trusted protocols.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2022–2025). Reported award amounts total $1,655,694. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.